OmniAbOABI
About: OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Employees: 114
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
243% more call options, than puts
Call options by funds: $120K | Put options by funds: $35K
12% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 17
9% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 46
0% more funds holding
Funds holding: 163 [Q3] → 163 (+0) [Q4]
14.99% less ownership
Funds ownership: 67.52% [Q3] → 52.53% (-14.99%) [Q4]
33% less capital invested
Capital invested by funds: $334M [Q3] → $225M (-$110M) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
RBC Capital Conor McNamara 13% 1-year accuracy 5 / 38 met price target | 121%upside $4 | Outperform Maintained | 27 Mar 2025 |
Benchmark Robert Wasserman 31% 1-year accuracy 13 / 42 met price target | 231%upside $6 | Buy Maintained | 20 Mar 2025 |
HC Wainwright & Co. Joseph Pantginis 16% 1-year accuracy 67 / 414 met price target | 508%upside $11 | Buy Reiterated | 19 Mar 2025 |
Financial journalist opinion









